NCT03893487 2025-07-11
PNOC016
University of California, San Francisco
Phase EARLY_PHASE1 Active not recruiting
Clinical Trials
3 trialsNCT05971758 2025-07-04
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
University of California, Los Angeles
Phase 2 Recruiting
NCT01742988 2021-05-06
Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma
Curis, Inc.
Phase 1 Completed